FDA Brief

Warning letters Drugs

FDA warning letter to

Health Plus Inc.

High riskIssued Dec 29, 2021Posted Jan 25, 2022Division of Pharmaceutical Quality Operations IV

FDA warned Health Plus Inc. over manufacturing quality failures in its Super Colon Cleanse laxative made in Chino, California.

What happened

FDA inspected Health Plus Inc.'s drug manufacturing facility in Chino, California, from June 23 to July 1, 2021. Investigators found the company resold returned capsules without adequate testing, made mixed batches from returned lots and gave them a new three-year shelf life, and had not validated the manufacturing process for Super Colon Cleanse after a December 2017 formulation change. FDA also found an unvalidated assay test method, no stability testing since at least September 2017, and a quality unit that had not approved key procedures; similar problems were cited in 2012, 2013, 2015 and 2018 inspections.

What FDA found

  1. The company resold returned drugs without proper inspection, investigation or testing, and combined capsules from different lots into new batches with a new three-year shelf life that stability data did not support.

    21 CFR 211.204
  2. The company changed the Super Colon Cleanse formulation in December 2017 but did not validate the new manufacturing process before releasing batches to the U.S. market.

    21 CFR 211.100(a)
  3. The company's test method used to release the laxative was not properly validated, including a wavelength that did not match its own specification and no system suitability check.

    21 CFR 211.165(e)
  4. The company's stability program was inadequate: it placed only a small amount of product on stability, did no stability testing since at least September 2017, and had no data to support the product's expiration date.

    21 CFR 211.166(a)
  5. The quality unit did not approve or reject all procedures and specifications affecting drug quality, including procedures for operating manufacturing equipment.

    21 CFR 211.22(c)

What FDA wants

FDA tells the company to correct the violations promptly and reply in writing within 15 working days with what it has done and its plan to prevent recurrence. FDA also strongly recommends hiring a qualified CGMP consultant to audit the whole operation.

Who should pay attention

  • retailers and online sellers that stock Super Colon Cleanse
  • contract manufacturers and packagers of over-the-counter laxatives
  • companies that accept, relabel or resell returned drug product

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk